Teva Pharmaceuticals Inc, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), announced on Friday the regulatory approval of its generic version of Forteo (teriparatide injection) in the United States.
This approval is set to enhance patient access to a crucial osteoporosis treatment. Market availability of the generic Forteo in the US is anticipated in the coming weeks.
Teriparatide injection is prescribed to address osteoporosis in specific demographics, including postmenopausal women at high fracture risk and men with primary or hypogonadal osteoporosis. It also caters to individuals with glucocorticoid-induced osteoporosis.
Forteo generated annual sales of USD609m as of July 2023, according to IQVIA data.
Teva has nearly 500 FDA-approved generic products, and 1 in 12 generic prescriptions dispensed in the United States is filled with a Teva generic product.
Its generic equivalent of Forteo employs the Antares Pharma Inc multi-dose pen device, part of an exclusive licence, development and supply agreement with Antares, a wholly owned subsidiary of Halozyme Therapeutics Inc (Nasdaq:HALO). This agreement encompasses the marketing of Teriparatide auto injector products in the EU and the forthcoming US market.
Clarity Pharmaceuticals starts registrational Phase III CLARIFY trial
Soligenix's Phase 2a SGX945 clinical trial IND application receives US FDA approval
Johnson & Johnson MedTech acquires Laminar in USD400m deal
Mithra Pharmaceuticals postpones DONESTA NDA filing to allow for additional analyses
GENinCode announces transition of CARDIO inCode-Score FDA submission to De Novo pathway
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
Orexo's OX124 New Drug Application accepted for review by US Food and Drug Administration
GE HealthCare expands Critical Care Suite with FDA-cleared Pneumothorax detection algorithm
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Orexo's opioid overdose rescue medication, OX124, gains FDA acceptance for review
SpringWorks Therapeutics' Ogsiveo tablets receive US FDA approval